Chromadex Corp.

( )
CDXC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
ARGXargenx SE -0.06%364.350.0%$114.52m
ICLRICON plc 1.44%220.632.8%$108.26m
VRXValeant Pharmaceuticals International, Inc. 20.50%8.7614.1%$51.55m
RVMDRevolution Medicines, Inc. -1.57%18.870.0%$18.72m
AMRNAmarin Corp. Plc -3.52%1.921.5%$8.75m
EVOKEvoke Pharma, Inc. 5.19%3.0439.7%$8.00m
USNAUSANA Health Sciences, Inc. 0.68%74.284.2%$5.51m
BGXXBright Green Corp. 1.79%2.840.0%$5.42m
ANIKAnika Therapeutics, Inc. -4.13%22.539.8%$3.30m
ATOSAtossa Therapeutics, Inc. 4.46%1.170.2%$2.69m
SMFLSmart for Life, Inc. 4.16%0.560.0%$1.70m
CDXCChromadex Corp. -9.01%1.922.7%$1.63m
IBIOiBio, Inc. 0.10%0.310.2%$1.35m
FLGCFlora Growth Corp. 1.39%0.730.0%$0.93m
NATRNature's Sunshine Products, Inc. -1.42%11.130.4%$0.89m

Company Profile

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.